CNS Specific Antisense Oligonucleotide Market Report Highlights The Competitive Scenario With Impact Of Drivers And Challenges 2026
Antisense
oligonucleotide plays a major role in modern healthcare, as it acts
on the messenger RNA level before the protein is formed to inhibit
expression of certain diseases-causing genes.
The global CNS
specific antisense oligonucleotide market size was valued at
US$ 883.7 million in 2017, and is expected to exhibit a CAGR of 24.9%
over the forecast period (2018 – 2026).
Increasing
prevalence of cancer is expected to propel growth of the CNS specific
antisense oligonucleotide market
CNS specific
antisense oligonucleotide is used for treatment of neurodegenerative
disorders and associated rare diseases. According to February 2017,
report of National Center for Biotechnology Information (NCBI), an
estimated the prevalence of Cerebral palsy ranges from 1.5 to more
than 4 per 1,000 of children from age 10 to 14 years. The birth
prevalence of Cerebral palsy is around 2 per 1,000 live births
globally.
Market Dynamics:
Increasing
prevalence of neurodegenerative disease is a major factor driving CNS
specific antisense oligonucleotide market growth. According to fact
sheet from Alzheimer Association, an estimated around 5.7 million
Americans were diagnosed with Alzheimer's dementia in 2018. Moreover,
rich product pipeline for the treatment of CNS disorders and rare
diseases associated with it is expected to boost the market growth.
For instance, in December 2018, Biogen and Ionis Pharmaceuticals
product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is
expected to be launched by 2020.
launch of new
products for rare disease associated with CNS disorders is propelling
growth of the CNS specific antisense oligonucleotide market over the
forecast period. For instance, in October 2018, Ionis
Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S.
Food and Drug Administration (FDA) approval for its novel drug
TEGSEDITM (inotersen) indicated for the treatment of the
polyneuropathy of hereditary transthyretin-mediated amyloidosis in
adults. In the same year, company received approval from Canadian
Health authority for the novel drug TEGSEDITM (inotersen).
Request For
Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2477
Detailed
Segmentation:
Global CNS
Specific Antisense Oligonucleotide Market, By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx
(RG6042)
Global CNS
Specific Antisense Oligonucleotide Market, By Indication:
Hereditary
transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular
Atrophy
Huntington’s
Disease
Global CNS
Specific Antisense Oligonucleotide Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global CNS
Specific Antisense Oligonucleotide Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Key Players
Major players
operating in the global CNS specific antisense oligonucleotide market
include Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc.,
Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd.,
Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., and
Q-STATE BIOSCIENCES, INC.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments
Post a Comment